Key result
Dexrazoxane is highlighted as an advance to prevent anthracycline cardiotoxicity, which becomes uncompensated after a lifetime doxorubicin dose of approximately /m2.
Why the study?
Does dexrazoxane prevent cardiotoxicity in children receiving anthracyclines?
Does dexrazoxane prevent cardiotoxicity in children receiving anthracyclines?
Answers are grounded in this paper and cite their sources.
Dexrazoxane represents an important advance in preventing the cumulative and irreversible cardiotoxicity associated with anthracycline use in cancer treatment, especially in pediatric populations.
Anthracyclines such as doxorubicin are among the most widely used anticancer drugs and are often given to children as part of curative regimens Yet long term cardiac damage is a major adverse effect that limits the effectiveness of these drugs, particularly in children. The introduction of dexrazoxane to limit the cardiotoxicity of anthracyclines is a real advance in the treatment of some forms of cancer. Cardiotoxicity induced by anthracyclines primarily affects the myocardium and is dose related, cumulative, and irreversible. Each dose of the anthracycline doxorubicin produces an increment of myocardial damage The normal heart can compensate for this until a lifetime dose of some 450 mg/m2 has been reached, after which the compensatory cardiac mechanisms begin to fail. In childhood malignancies, which may be cured if sufficient anthracyclines can be given, cardiotoxicity is more erratic and severe than in adults.1 Each dose may unpredictably cause severe toxicity, or subclinical cardiotoxicity may become overt only in adolescence or early adulthood.2 A way of preventing cardiotoxicity in children taking anthracyclines will therefore prevent not …
No takes yet. Share an insight, caveat, or question.
K. Hellmann (1999) conducted an editorial in Anthracycline-induced cardiotoxicity. Dexrazoxane was evaluated. Dexrazoxane is highlighted as an advance to prevent anthracycline cardiotoxicity, which becomes uncompensated after a lifetime doxorubicin dose of approximately /m2.
Synapse has enriched 10 related papers. Consider them for comparative context: